Wednesday 14 June 2017

Trastuzumab Combined Oxaliplatin and S-1 Therapy Demonstrated Pathological Complete Response of Synchronous Liver Metastasis of Gastric Cancer

Liver Metastasis of Gastric Cancer
The HER2 positive advanced or metastatic gastric cancer (GC) is recommended with Trastuzumab (Tmab) combined cisplatin (CDDP) and capecitabine (Cap).

Otherwise, oxaliplatin (L-OHP) has been replaced in place of CDDP for GC. Furthermore, S-1 is a key oral anticancer drug used in the treatment of gastrointestinal cancer in Asia.

A 59- year-old man who received Tmab-SOX therapy for solitary synchronous liver metastasis of GC, because the operated intestinal type GC revealed HER2 score 3+ immunohistochemically.

No comments:

Post a Comment